Masimo (NASDAQ:MASI) today announced the findings of a prospective study published in Pediatrics International in which Dr. Ya-Fei Liu and colleagues at Peking University First Hospital in Beijing evaluated the ability of noninvasive, continuous Masimo PVi®, alongside other dynamic parameters, to predict fluid responsiveness in children 1-3 years old who were undergoing major neurosurgery. The researchers concluded, “Volume-based PVi and ∆Vpeak [respiratory variation in aortic blood flow peak velocity] showed acceptable reliabilities for fluid responsiveness prediction in young children undergoing major neurosurgery, while pressure-based SVV [stroke volume variation] using FloTrac/Vigileo, Eadyn [dynamic arterial elastance], and PPV [pulse pressure variation] [did] not.”1
Study Finds That Masimo PVi Capable Of Predicting Fluid Responsiveness in Young Children Undergoing Neurosurgery
Masimo (NASDAQ:MASI) today announced the findings of a prospective study published in Pediatrics International in which Dr. Ya-Fei Liu and colleagues at Peking University First Hospital in Beijing
Related Posts
Bitfarms Mines 3,452 Bitcoin In 2021
Today, 12:12 PM
Bitfarms Ltd. (NASDAQ:BITF, TSXV:BITF), a global Bitcoin self-mining company, provides a Bitcoin (BTC) production and operations summary and update for the month of and year ended December 2021.
"We began 2021
Analysts Slash Price Targets After Theravance’s Failed Ulcerative Colitis Study
Today, 12:12 PM
Analysts have lowered the price target and downgraded Theravance Biopharma Inc (NASDAQ: TBPH) after disappointing ulcerative colitis Phase 2 trial data.